Lindy Paulina Johanna Arts1, Rick Waalboer-Spuij2,3, Kees-Peter de Roos4, Monique R T M Thissen5,6,7, Luc J Scheijmans8, Mieke J Aarts9, Simone Oerlemans9, Marnix L M Lybeert10, Marieke W J Louwman9. 1. Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands, l.arts@iknl.nl. 2. Department of Dermatology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands. 3. Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands. 4. Department of Dermatology, DermaPark, Uden, The Netherlands. 5. Department of Dermatology, Catharina Hospital, Eindhoven, The Netherlands. 6. Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands. 7. GROW, School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. 8. Department of Radiation Oncology, Dr. Bernard Verbeeten Institute, Tilburg, The Netherlands. 9. Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands. 10. Department of Radiation Oncology, Catharina Hospital, Eindhoven, The Netherlands.
Abstract
BACKGROUND: Little is known about the impact of keratinocyte cancer (KC) and its treatment on health-related quality of life (HRQoL). OBJECTIVES: The objectives of the present study were (1) to evaluate HRQoL among patients with KC in a population-based setting and compare this with an age- end sex-matched normative population and (2) to compare HRQoL, satisfaction with care, and cosmetic results among patients who underwent conventional excision, Mohs' micrographic surgery, or radiotherapy. METHOD: A random sample of 347 patients diagnosed with cutaneous basal cell or squamous cell carcinoma in the head and neck area between January 1, 2010, and December 31, 2014, were selected from the Netherlands Cancer Registry (NCR) and were invited to complete a questionnaire on HRQoL, satisfaction with care, and cosmetic results. Data were collected within Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship (PROFILES). Outcomes were compared to an age- and sex-matched normative population. RESULTS: Two hundred fifteen patients with KC returned a completed questionnaire (62% response). Patients with KC reported better global quality of life (79.6 vs. 73.3, p < 0.01) and less pain (p < 0.01) compared to the normative population. No statistically significant differences in HRQoL, satisfaction with care, and cosmetic results were found between patients with KC who underwent conventional excision, Mohs' micrographic surgery, or radiotherapy. CONCLUSIONS: The impact of KC and its treatment seems relatively low and more positive than negative as patients reported better HRQoL compared to an age- and sex-matched normative population, probably due to adaptation. No statistically significant differences between treatment types were found concerning HRQoL, patient satisfaction, and cosmetic results. This information could be used by healthcare professionals involved in KC care to improve patients' knowledge about different aspects of the disease as patient's preference is an important factor for treatment choice. The Author(s). Published by S. Karger AG, Basel.
BACKGROUND: Little is known about the impact of keratinocyte cancer (KC) and its treatment on health-related quality of life (HRQoL). OBJECTIVES: The objectives of the present study were (1) to evaluate HRQoL among patients with KC in a population-based setting and compare this with an age- end sex-matched normative population and (2) to compare HRQoL, satisfaction with care, and cosmetic results among patients who underwent conventional excision, Mohs' micrographic surgery, or radiotherapy. METHOD: A random sample of 347 patients diagnosed with cutaneous basal cell or squamous cell carcinoma in the head and neck area between January 1, 2010, and December 31, 2014, were selected from the Netherlands Cancer Registry (NCR) and were invited to complete a questionnaire on HRQoL, satisfaction with care, and cosmetic results. Data were collected within Patient-Reported Outcomes Following Initial Treatment and Long-term Evaluation of Survivorship (PROFILES). Outcomes were compared to an age- and sex-matched normative population. RESULTS: Two hundred fifteen patients with KC returned a completed questionnaire (62% response). Patients with KC reported better global quality of life (79.6 vs. 73.3, p < 0.01) and less pain (p < 0.01) compared to the normative population. No statistically significant differences in HRQoL, satisfaction with care, and cosmetic results were found between patients with KC who underwent conventional excision, Mohs' micrographic surgery, or radiotherapy. CONCLUSIONS: The impact of KC and its treatment seems relatively low and more positive than negative as patients reported better HRQoL compared to an age- and sex-matched normative population, probably due to adaptation. No statistically significant differences between treatment types were found concerning HRQoL, patient satisfaction, and cosmetic results. This information could be used by healthcare professionals involved in KC care to improve patients' knowledge about different aspects of the disease as patient's preference is an important factor for treatment choice. The Author(s). Published by S. Karger AG, Basel.
Authors: Rick Waalboer-Spuij; Loes M Hollestein; Reinier Timman; Lonneke V van de Poll-Franse; Tamar E Nijsten Journal: Acta Derm Venereol Date: 2018-02-07 Impact factor: 4.437
Authors: A Brédart; A Bottomley; J M Blazeby; T Conroy; C Coens; S D'Haese; Wei-Chu Chie; E Hammerlid; J I Arraras; F Efficace; C Rodary; S Schraub; M Costantini; A Costantini; F Joly; O Sezer; D Razavi; M Mehlitz; M Bielska-Lasota; N K Aaronson Journal: Eur J Cancer Date: 2005-09 Impact factor: 9.162
Authors: Lonneke V van de Poll-Franse; Floortje Mols; Chad M Gundy; Carien L Creutzberg; Remi A Nout; Irma M Verdonck-de Leeuw; Martin J Taphoorn; Neil K Aaronson Journal: Eur J Cancer Date: 2010-12-04 Impact factor: 9.162
Authors: F Joly; J F Héron; L Kalusinski; P Bottet; D Brune; N Allouache; J Macé-Lesec'h; J E Couëtte; J Pény; M Henry-Amar Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: Todd V Cartee; Murad Alam; Eric S Armbrecht; Anit Behera; Naomi Lawrence; Jeremy S Bordeaux; Christian L Baum; Anthony Rossi; Ian A Maher Journal: Dermatol Surg Date: 2019-02 Impact factor: 3.398
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506